France’s Saint‑Julien site adds a bioprocess development suite for upstream/downstream scale-up of recombinant proteins, including complex mAbs and ADCs, and doubles bioconjugation capacity. Rodano, ...

Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the completion of ...

Axplora, a German CDMO that specializes in specialty active pharmaceutical ingredients for small molecules and antibody-drug ...

Wilmington PharmaTech, a CRDMO that specializes in complex custom active pharmaceutical ingredients (API) for small molecules ...

BOCA RATON, Fla.-- (BUSINESS WIRE)--March 19, 2026-- ...

Cambrex is expanding US and European operations with major investments in Iowa and Milan, boosting API capacity and R and D ...

While the United Kingdom feted President Trump in his second state visit, GSK said Wednesday it will spend $30 billion over the next five years to build new manufacturing and research facilities ...

EAST RUTHERFORD, N.J., Oct. 22, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced a $120 million investment to expand its U.S.

AstraZeneca, a pharmaceutical company, has announced its plans to bring a drug substance manufacturing facility to Virginia.

Scheduled for August 2025 completion, the initial $2-billion phase included construction of a 1-million-sq-ft complex with two drug substance manufacturing buildings, each containing four 20,000-liter ...

Drug Substance manufacturing is a critical component of pharmaceutical production, requiring precise processes, rigorous quality control, and innovative solutions to overcome various challenges. From ...

India hosts more active pharmaceutical ingredient (API) manufacturing sites that are compliant with the U.S. Food and Drug Administration than any country outside the U.S., and it produces more ...